Abstract
Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Current Drug Discovery Technologies
Title: Targeting Apoptosis to Treat Multiple Sclerosis
Volume: 5 Issue: 1
Author(s): George S. Robertson, Andrea L.O. Hebb, Craig S. Moore and Virender Bhan
Affiliation:
Abstract: Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Export Options
About this article
Cite this article as:
Robertson S. George, Hebb L.O. Andrea, Moore S. Craig and Bhan Virender, Targeting Apoptosis to Treat Multiple Sclerosis, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769432
DOI https://dx.doi.org/10.2174/157016308783769432 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Immunogenetic Mechanisms Leading to Thyroid Autoimmunity: Recent Advances in Identifying Susceptibility Genes and Regions
Current Genomics “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Microwave Assisted Organic Synthesis of Heterocycles in Aqueous Media: Recent Advances in Medicinal Chemistry
Medicinal Chemistry Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala
Current Neuropharmacology New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
Current Gene Therapy Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Discovery of Inhibitors of Protein-Protein Interactions from Combinatorial Libraries
Current Topics in Medicinal Chemistry Activation of Calpain and Caspase Pathways in Demyelination and Neurodegeneration in Animal Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Engineering Simulations for Cancer Systems Biology
Current Drug Targets Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry